S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   277.20 (+2.08%)
AAPL   114.96 (+2.39%)
MSFT   209.44 (+0.78%)
FB   256.82 (+0.78%)
GOOGL   1,458.66 (+1.36%)
AMZN   3,174.05 (+2.55%)
TSLA   421.20 (+3.40%)
NVDA   521.40 (+1.25%)
BABA   276.01 (+1.81%)
CGC   14.21 (+0.28%)
GE   6.20 (+1.47%)
MU   49.72 (+1.18%)
AMD   79.48 (+1.82%)
T   28.38 (+1.21%)
F   6.69 (+2.76%)
ACB   4.78 (-5.35%)
GILD   62.85 (+0.96%)
NFLX   490.65 (+1.61%)
DIS   125.99 (+1.60%)
BA   166.08 (+6.44%)
BAC   24.09 (+2.55%)
S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   277.20 (+2.08%)
AAPL   114.96 (+2.39%)
MSFT   209.44 (+0.78%)
FB   256.82 (+0.78%)
GOOGL   1,458.66 (+1.36%)
AMZN   3,174.05 (+2.55%)
TSLA   421.20 (+3.40%)
NVDA   521.40 (+1.25%)
BABA   276.01 (+1.81%)
CGC   14.21 (+0.28%)
GE   6.20 (+1.47%)
MU   49.72 (+1.18%)
AMD   79.48 (+1.82%)
T   28.38 (+1.21%)
F   6.69 (+2.76%)
ACB   4.78 (-5.35%)
GILD   62.85 (+0.96%)
NFLX   490.65 (+1.61%)
DIS   125.99 (+1.60%)
BA   166.08 (+6.44%)
BAC   24.09 (+2.55%)
S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   277.20 (+2.08%)
AAPL   114.96 (+2.39%)
MSFT   209.44 (+0.78%)
FB   256.82 (+0.78%)
GOOGL   1,458.66 (+1.36%)
AMZN   3,174.05 (+2.55%)
TSLA   421.20 (+3.40%)
NVDA   521.40 (+1.25%)
BABA   276.01 (+1.81%)
CGC   14.21 (+0.28%)
GE   6.20 (+1.47%)
MU   49.72 (+1.18%)
AMD   79.48 (+1.82%)
T   28.38 (+1.21%)
F   6.69 (+2.76%)
ACB   4.78 (-5.35%)
GILD   62.85 (+0.96%)
NFLX   490.65 (+1.61%)
DIS   125.99 (+1.60%)
BA   166.08 (+6.44%)
BAC   24.09 (+2.55%)
S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   277.20 (+2.08%)
AAPL   114.96 (+2.39%)
MSFT   209.44 (+0.78%)
FB   256.82 (+0.78%)
GOOGL   1,458.66 (+1.36%)
AMZN   3,174.05 (+2.55%)
TSLA   421.20 (+3.40%)
NVDA   521.40 (+1.25%)
BABA   276.01 (+1.81%)
CGC   14.21 (+0.28%)
GE   6.20 (+1.47%)
MU   49.72 (+1.18%)
AMD   79.48 (+1.82%)
T   28.38 (+1.21%)
F   6.69 (+2.76%)
ACB   4.78 (-5.35%)
GILD   62.85 (+0.96%)
NFLX   490.65 (+1.61%)
DIS   125.99 (+1.60%)
BA   166.08 (+6.44%)
BAC   24.09 (+2.55%)
Log in
NASDAQ:TPTX

Turning Point Therapeutics Stock Forecast, Price & News

$89.33
+2.64 (+3.05 %)
(As of 09/28/2020 04:30 PM ET)
Add
Compare
Today's Range
$86.36
Now: $89.33
$89.85
50-Day Range
$56.99
MA: $72.42
$88.57
52-Week Range
$31.30
Now: $89.33
$89.85
Volume267,651 shs
Average Volume370,100 shs
Market Capitalization$3.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.39
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.08 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TPTX
CUSIPN/A
CIKN/A
Phone858-926-5251

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$11.28 per share

Profitability

Net Income$-72,130,000.00

Miscellaneous

Employees50
Market Cap$3.77 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
$89.33
+2.64 (+3.05 %)
(As of 09/28/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TPTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions

How has Turning Point Therapeutics' stock been impacted by Coronavirus?

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TPTX stock has increased by 120.4% and is now trading at $89.33.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Turning Point Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Turning Point Therapeutics
.

When is Turning Point Therapeutics' next earnings date?

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Turning Point Therapeutics
.

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics (NASDAQ:TPTX) issued its quarterly earnings results on Monday, August, 10th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.07.
View Turning Point Therapeutics' earnings history
.

What price target have analysts set for TPTX?

6 brokers have issued 12-month price objectives for Turning Point Therapeutics' shares. Their forecasts range from $67.00 to $100.00. On average, they expect Turning Point Therapeutics' share price to reach $82.50 in the next year. This suggests that the stock has a possible downside of 7.6%.
View analysts' price targets for Turning Point Therapeutics
.

Who are some of Turning Point Therapeutics' key competitors?

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), Opko Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD), GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ).

Who are Turning Point Therapeutics' key executives?

Turning Point Therapeutics' management team includes the following people:
  • Dr. Athena Maria Countouriotis, Pres, CEO & Director (Age 47)
  • Dr. Jingrong Jean Cui Ph.D., Scientific Founder, Chief Scientific Officer & Director (Age 55)
  • Mr. Brian L. Baker MS, CPA, VP of Fin. & Admin. (Age 52)
  • Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor Relations
  • Ms. Annette C. North, Exec. VP, Gen. Counsel & Company Sec.

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an IPO on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Who are Turning Point Therapeutics' major shareholders?

Turning Point Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (12.04%), Vanguard Group Inc. (6.60%), Cormorant Asset Management LP (6.49%), Jennison Associates LLC (1.77%), Federated Hermes Inc. (1.69%) and Goldman Sachs Group Inc. (1.13%). Company insiders that own Turning Point Therapeutics stock include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Jingrong Jean Cui, Simeon George and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics
.

Which institutional investors are selling Turning Point Therapeutics stock?

TPTX stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Deerfield Management Company L.P. Series C, Nicholas Investment Partners LP, Driehaus Capital Management LLC, Perceptive Advisors LLC, UBS Group AG, Strs Ohio, and Chartwell Investment Partners LLC.
View insider buying and selling activity for Turning Point Therapeutics
.

Which institutional investors are buying Turning Point Therapeutics stock?

TPTX stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Goldman Sachs Group Inc., First Light Asset Management LLC, Federated Hermes Inc., Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, and Handelsbanken Fonder AB. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Simeon George, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics
.

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $89.33.

How big of a company is Turning Point Therapeutics?

Turning Point Therapeutics has a market capitalization of $3.77 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 50 workers across the globe.

What is Turning Point Therapeutics' official website?

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.